A citation-based method for searching scientific literature

Kristine R Broglio, Donald A Berry. J Natl Cancer Inst 2009
Times Cited: 344







List of co-cited articles
402 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
17


Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Tomasz Burzykowski, Marc Buyse, Martine J Piccart-Gebhart, George Sledge, James Carmichael, Hans-Joachim Lück, John R Mackey, Jean-Marc Nabholtz, Robert Paridaens, Laura Biganzoli,[...]. J Clin Oncol 2008
245
12

Progression-free survival is a surrogate for survival in advanced colorectal cancer.
Marc Buyse, Tomasz Burzykowski, Kevin Carroll, Stefan Michiels, Daniel J Sargent, Langdon L Miller, Gary L Elfring, Jean-Pierre Pignon, Pascal Piedbois. J Clin Oncol 2007
262
11

Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.
Katsuyuki Hotta, Katsuyuki Kiura, Yoshiro Fujiwara, Nagio Takigawa, Akiko Hisamoto, Eiki Ichihara, Masahiro Tabata, Mitsune Tanimoto. PLoS One 2011
58
17

Progression-free survival: meaningful or simply measurable?
Christopher M Booth, Elizabeth A Eisenhauer. J Clin Oncol 2012
205
10


Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
Martin Reck, Joachim von Pawel, Petr Zatloukal, Rodryg Ramlau, Vera Gorbounova, Vera Hirsh, Natasha Leighl, Jörg Mezger, Venice Archer, Nicola Moore,[...]. J Clin Oncol 2009
9



Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.
Hisao Imai, Keita Mori, Akira Ono, Hiroaki Akamatsu, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo,[...]. Med Oncol 2014
13
61


Palbociclib and Letrozole in Advanced Breast Cancer.
Richard S Finn, Miguel Martin, Hope S Rugo, Stephen Jones, Seock-Ah Im, Karen Gelmon, Nadia Harbeck, Oleg N Lipatov, Janice M Walshe, Stacy Moulder,[...]. N Engl J Med 2016
8

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Richard S Finn, John P Crown, Istvan Lang, Katalin Boer, Igor M Bondarenko, Sergey O Kulyk, Johannes Ettl, Ravindranath Patel, Tamas Pinter, Marcus Schmidt,[...]. Lancet Oncol 2015
8

Clinical significance of post-progression survival in lung cancer.
Hisao Imai, Kyoichi Kaira, Koichi Minato. Thorac Cancer 2017
30
26

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.
Kent R Johnson, Clare Ringland, Barrie J Stokes, Danielle M Anthony, Nick Freemantle, Alar Irs, Suzanne R Hill, Robyn L Ward. Lancet Oncol 2006
137
7

Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer.
Katsuyuki Hotta, Yoshiro Fujiwara, Keitaro Matsuo, Katsuyuki Kiura, Nagio Takigawa, Masahiro Tabata, Mitsune Tanimoto. J Thorac Oncol 2009
53
13

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
7

A statistical model for the dependence between progression-free survival and overall survival.
Frank Fleischer, Birgit Gaschler-Markefski, Erich Bluhmki. Stat Med 2009
38
18

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
7

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.
Hisao Imai, Keita Mori, Kazushige Wakuda, Akira Ono, Hiroaki Akamatsu, Takehito Shukuya, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Kyoichi Kaira,[...]. Ann Thorac Med 2015
27
25

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
Xavier Paoletti, Koji Oba, Yung-Jue Bang, Harry Bleiberg, Narikazu Boku, Olivier Bouché, Paul Catalano, Nozomu Fuse, Stefan Michiels, Markus Moehler,[...]. J Natl Cancer Inst 2013
56
10

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
793
6

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
788
6



Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
Hidetoshi Hayashi, Isamu Okamoto, Masataka Taguri, Satoshi Morita, Kazuhiko Nakagawa. Clin Lung Cancer 2013
29
20

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
6

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Kathy Miller, Molin Wang, Julie Gralow, Maura Dickler, Melody Cobleigh, Edith A Perez, Tamara Shenkier, David Cella, Nancy E Davidson. N Engl J Med 2007
6

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Gabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, Yoon-Sim Yap, Gabe S Sonke, Shani Paluch-Shimon, Mario Campone, Kimberly L Blackwell, Fabrice André, Eric P Winer,[...]. N Engl J Med 2016
820
6

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A Kaufman,[...]. J Clin Oncol 2017
605
6


Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
6


Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
Michelle K Wilson, Katherine Karakasis, Amit M Oza. Lancet Oncol 2015
103
5


A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
5



The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
N K Aaronson, S Ahmedzai, B Bergman, M Bullinger, A Cull, N J Duez, A Filiberti, H Flechtner, S B Fleishman, J C de Haes. J Natl Cancer Inst 1993
5


RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Nicholas J Robert, Véronique Diéras, John Glaspy, Adam M Brufsky, Igor Bondarenko, Oleg N Lipatov, Edith A Perez, Denise A Yardley, Stephen Y T Chan, Xian Zhou,[...]. J Clin Oncol 2011
699
5

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
Hope S Rugo, R Bryan Rumble, Erin Macrae, Debra L Barton, Hannah Klein Connolly, Maura N Dickler, Lesley Fallowfield, Barbara Fowble, James N Ingle, Mohammad Jahanzeb,[...]. J Clin Oncol 2016
308
5

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Nicholas C Turner, Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Cynthia Huang Bartlett, Ke Zhang,[...]. N Engl J Med 2015
834
5

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
5

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Debu Tripathy, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Nadia Harbeck, Sara A Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee,[...]. Lancet Oncol 2018
311
5

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Dennis J Slamon, Patrick Neven, Stephen Chia, Peter A Fasching, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, Giulia Val Bianchi, Francisco J Esteva, Miguel Martín,[...]. J Clin Oncol 2018
347
5

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Matthew P Goetz, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch-Shimon, Jens Huober, In Hae Park, Olivier Trédan, Shin-Cheh Chen, Luis Manso,[...]. J Clin Oncol 2017
565
5

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Takashi Seto, Terufumi Kato, Makoto Nishio, Koichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa,[...]. Lancet Oncol 2014
481
5

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
S Delaloge, D Pérol, C Courtinard, E Brain, B Asselain, T Bachelot, M Debled, V Dieras, M Campone, C Levy,[...]. Ann Oncol 2016
45
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.